Its dual mechanism of inhibiting AhR and PD-1/PD-L1 pathways, combined with favorable pharmacokinetics and strong in vivo efficacy, highlights its promise as a therapeutic candidate for colorectal cancer, particularly in combination with existing immunotherapies. This evidence concerns the gene AHR and colorectal cancer.